in both HL60 and CLL cells (Figures 3a and c) . MX enhanced fludarabine-cytotoxicity by threefold ( n Po0.05) when compared with fludarabine treatment alone. In addition, MX potentiated the therapeutic efficacy of fludarabine as evidenced in HL60 xenografts in nude mice. As shown in Figure 3b and a, moderate sensitivity to fludarabine alone was observed in HL60 xenografts; however, significant inhibition of tumor growth was seen after the combined fludarabine plus MX treatment. At 17 days, HL60 xenografts treated with PBS (control group) had a mean tumor volume of 2500±106 mm 3 compared with a mean tumor volume of 1456 ± 76 mm 3 and 643 ± 142 mm 3 ( n Po0.05) in mice treated with either fludarabine alone or with the combined fludarabine plus MX treatment, respectively. These results demonstrate that the disruption of the BER by MX increased the magnitude of the response to fludarabine. MX alone did not affect tumor growth, displaying a similar growth rate to that observed in control group. At these doses, mice did not present any evidence of toxicity as evaluated by measurements of body weight and whole blood toxicity analysis. To further confirm that MX enhanced cytotoxicity of fludarabine is associated with the cellular levels of UDG and topo II a, normal bone marrow cells were treated with fludarabine alone and in combination with MX. Results showed that MX did not appear to increase the cytotoxicity observed with fludarabine alone in normal bone marrow cells, presumably, because these cells express lower levels of both UDG and topo II a compared with tumor cells. 7 These results strongly suggest that the induced killing effect of the combination treatment of fludarabine and MX would be selective toward tumor cells, which would be relatively protective of normal bone marrow cells.
In summary, we demonstrate that (i) a new mechanism, the BER pathway, is involved in processing incorporated fludarabine, as well as mis-incorporated uridine in DNA through the enzymatic activity of UDG; (ii) MX binding of AP-sites generated directly and indirectly by fludarabine induces un-repairable DNA damage that can block the BER pathway; and (iii) MX potentiates the therapeutic efficacy of fludarabine, allowing for the possibility of a novel therapeutic strategy to combine inhibitors of BER with fludarabine for clinical treatment. Targeting BER as a target-based therapeutic strategy can be extended to the combination of MX with a number of other drugs that incorporate into DNA either by acting as nucleotide analogs or through the manipulation of the nucleotide pools. mutations can occur in homozygous configurations. Assays of JAK2V617F mutant allele burden consequent to UPD are increasingly being utilized clinically because of diagnostic and prognostic relevance. Based on these observations, it can be postulated that areas of somatic UPD may identify regions that harbor mutations in the regions affected by the copy number neutral loss of heterozygosity/UPD. 7 If found, somatic UPD most often spans large areas of the affected chromosome, thus making identification of mutated target genes quite challenging.
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However, high-density SNP-A can also allow for the detection of submicroscopic microdeletions, which have proven helpful in narrowing the search for mutant genes. 1 Mapping of such microdeletions was instrumental in the ultimate identification of TET2 and CBL mutations, which were found to be present in the hemizygous configuration in the regions affected by microdeletions. 3 Often, portions of chromosomes affected by loss of heterozygosity (LOH) due to both UPD and deletions overlap Letters to the Editor (4q24 and 11q23, for example). Interestingly, other recurrently deleted areas associated with myeloid malignancies, such as del(20q) and del(5q), are rarely associated with a UPD at the same location. 7 To date, no mutations have been associated with UPD7 in myeloid malignancy, although several of them have been excluded: for example, MET, EPHA1 and BRAF genes. 2 Recent work has identified mutations in an interesting series of genes involved in the modification of chromatin structure and epigenetic regulation in myeloid malignancies. These include the polycomb-associated genes UTX and ASXL1, as well as TET2. 4 While TET2 mutations can be in heterozygous, hemizygous, or homozygous configuration, ASXL1 and UTX mutations have been generally identified in a heterozygous configuration. We recently identified UTX mutations in chronic myelomonocytic leukemia (CMML) based on SNP-A findings (manuscript in review).
Based on this information, we sought to identify the gene(s) that might be mutated and drive the generation of UPD7 in myeloid malignancies. Previously, we reviewed SNP-A karyograms in a large screen of myeloid malignancies, 7 and identified 15 patients with somatic UPD of the long arm of chromosome 7. This analysis also revealed the presence of several different microdeletions that could define a commonly affected region, and thereby narrow the search for pathogenically mutated genes. For the identification of such a mutation, we utilized two strategies: (i) we employed the so-called next-generation sequencing platform (NGS) to identify mutations that may be present in the areas of UPD and (ii) we systematically sequenced genes contained in the overlapping microdeletion regions.
SNP-A-based karyotyping facilitated mapping of regions affected by UPD7q (Figure 1 ). In total, 15 patients with UPD7q were identified and a number of patients with monosomy 7 and del(7q) were also analyzed ( Table 1) . Because of the large size of the commonly affected area involving UPD (7q31.33-qter), we applied the NGS approach for the identification of affected genes. We generated exome chromosome 7 libraries that were enriched for the content of chromosome 7 coding sequences using the SureSelect capture synthetic biotinylated RNA probes from Agilent (Santa Clara, CA, USA), tiling all the coding regions from chromosome 7. Libraries were generated from two cases with UPD7q and subjected to high-throughput sequencing on an Illumina Genome Analyzer IIx (San Diego, CA, USA). In one of the sequenced patients with MDS and UPD7q (patient no. 1), following bioinformatic exclusion procedures to eliminate possible spurious sequence alterations, we focused on 34 putative non-synonymous alterations (out of 45000 variant event calls). These 34 alterations were subjected to manual confirmation using traditional sequencing, and a missense mutation C to T was confirmed to be present in base pair position 148137376 of the EZH2 gene on chromosome 7. This mutation results in a predicted amino-acid change, 690Arg-His. At this specific locus all of 26 sequences showed the mutated allele (Figure 1 ). The somatic origin of this homozygous sequence alteration was confirmed by Sanger sequencing of DNA derived from tissue isolated from a separate skin biopsy (Figure 2 ). The second UPD7 NGS case showed no mutations in EZH2 (data not shown).
In total, our sequencing analysis involved 344 patients in all of whom SNP-array karyotyping was performed using primers for exons 16-19 covering the whole SET domain of EZH2 ( Table 1 ). In our SNP-A screen of patients with del(7q) we identified two patients with overlapping microdeletion involving 7q36.1 (Figure 1b) . The minimally affected area defined by one of the patients contained two genes, CUL1 and EZH2 (patient no. 5). We sequenced all exons of both genes and did not find any mutations in CUL1. However, we detected a mutation in EZH2 located in an exon 19 in the proximity of the mutation detected through the NSG-sequencing approach. The mutation involved position Ile715 and produced a frameshift ( Table 2 , Figures 1c and 2b) .
We hypothesized that other patients with UPD7q and del(7q) might harbor EZH2 mutations and sought to establish the mutational frequency within this group of patients and compare this with those with similar myeloid malignancies, but not affected by LOH in the 7q region. In total, sequencing EZH2 was performed in 15 patients with UPD7q, 30 patients with del(7q) or monosomy 7, and 299 patients without these defects ( Table 1) . We found four different EZH2 mutations present in 3/15 (20%) patients with UPD7q and 2/30 (7%) patients with del(7q). In a patient without LOH7q (patient no. 6), a frameshift mutation affected the Leu727 residue and heterozygosity was confirmed by subcloning technique (Figure 2e ). Of note is that both hemizygous mutations were found in patients with microdeletions and none of the patients with large del(7q) or monosomy 7 harbored the EZH2 mutation. There were four missense and two frameshift mutations, all located in exon 18 or 19 coding for SET domain of the EZH2 gene (Figure 2) . Strikingly, mutations altering Tyr641, previously identified in a number of B-cell lymphoma patients, were not found in any of our patients screened. 8 We next analyzed the clinical features of patients who harbored EZH2 mutations. Two patients had transfusiondependent refractory cytopenia with multilineage dysplasia, while three had myelomonocytoid malignancies, including CMML (N ¼ 2) and acute myelomonocytic leukemia (M4) (N ¼ 1), and one patient had MDS/MPN unclassifiable (Table 2) . Thus, 3/6 patients with EZH2 gene mutation had histomorphological features consistent with MDS/MPN overlap. Regarding cytogenetic associations, trisomy 8 was present in two patients with CMML, while only one patient showed an entirely normal karyotype by both SNP-A and metaphase cytogenetics. We did not identify any other distinctive clinical features. Overall, EZH2 mutations were detected in 2/25 cases of CMML studied (and 3/83 MDS/MPN), consistent with the high prevalence of somatic UPD7 in this disease entity. Two out of 131 cases of MDS (not including CMML) were affected. Mutations were not identified in any of the classical MPN cases; however, relatively small numbers of cases were studied here. Interestingly, metaphase cytogenetics indicated no abnormality in chromosome 7 in any of the EZH2 mutant cases, but SNP-A karyotyping was useful for detection of cryptic LOH7q in 5/6 patients with EZH2 mutations. Our observation is now added to the growing list of recently identified mutations of genes involved in chromatin remodeling and epigenetic regulation within myeloid malignancies. These include ASXL1, TET2, SETD2, JARID1C and UTX. 8 Mutations of these genes may generate a clonally restricted, epigenetic instability phenotype. For example, TET2 may participate in conversion of 5-hydroxymethylcytosine to 5-methylcytosine, and thereby facilitate DNA demethylation through prevention of the maintenance function of DNMT1; thus, loss of function of this gene could lead to an increase of aberrant methylation. ASXL1 has a PHD finger, and helps to recruit polycomb and trithorax complexes to specific chromatin domains. LSD1 Figure 2 Types of EZH2 mutations in myeloid malignancy. (a) In a patient with refractory cytopenia with multilineage dysplasia (RCMD; patient no. 1), UPD 7q31.33qter was detected by genome-wide 6.0 SNP-A analysis (left panel). A homozygous missense mutation (R690H) was seen in the SET domain of EZH2 in bone marrow (middle panel), but WT sequence at this site was confirmed using germ-line DNA obtained from skin biopsy (right panel). (b) A microdeletion 7q36.1 was detected in the EZH2 locus in a patient with RCMD (patient no. 5) (left panel), leading to a hemizygous frameshift mutation (I715Pfs) in the whole BM sample (middle panel). This mutation was more obvious by testing purified granulocytes (right panel), strongly suggesting the somatic nature of this mutation. (c) In a patient with AML (M4) (patient no. 3), UPD 7q31.32qter was seen by Affymetrix 250K array as illustrated by CNAG 2.0 software data output. In the left panel, the blue line represents the copy number (CN) signal intensity of SNP probes. In this instance there are no CN variations, and thus the blue line does not deviate from normal diploid CN. The green marks below the idiogram represent heterozygosity at particular DNA loci. Between 7q31.32 and qter, a drastic reduction of heterozygous loci denotes the region of UPD. Allele-specific copy number analysis also reveals the presence of UPD, with two copies of a major allele (green line) and deletion of the minor allele (red line). In the marrow sample, a missense mutation (N693T) was detected in the SET domain Letters to the Editor cooperates with ASXL1 in transcriptional repression, presumably by removing H3K4 methylation, an active histone mark, but not H3K9 methylation, a repressive histone mark recognized by HP1. UTX and EZH2 are involved in the regulation of the methylation status of histone H3. UTX demethylates trimethylated H3K27 (H3K27me3). H3K27me3 blocks the transcription of genes necessary for differentiation by the maintenance of repression mark. Consequently, inactivation of UTX may impair differentiation. This is in agreement with our observation that UTX mutations were encountered more often in patients with AML. EZH2 is another polycomb-associated gene that encodes a methyltransferase and targets H3K27, thereby producing a repressive mark. Loss of function or hypomorphic mutations of EZH2 would thus be predicted to result in abrogation of inhibitory chromatin marks and chromatin decompaction, likely promoting expression of oncogenic genes.
EZH2 mutations occurring in large B-cell lymphomas affect only one position, resulting in the replacement of a single tyrosine in the SET domain of the EZH2 protein (Y641) and thereby reduced enzymatic activity, at least in vitro. 8 A western blot performed on bone marrow lysates showed that mutations identified in EZH2 in myeloid malignancies lead to decreased methylation of H3K27 and thereby are functionally relevant in the patients with EZH2 mutations (Figure 3) . Unlike the lymphoma-associated Y641 mutation, EZH2 mutations that we have identified in 5/6 myeloid malignancies lead to inactivation of both alleles (UPD7q and microdeletion 7q36.1). Only 1/6 myeloid EZH2 mutations were found in the heterozygous configuration. However, the question still remains as to why patients with monosomy 7 or del(7q) were not affected. It appears that EZH2 mutations are not driver mutations in clones characterized by monosomy 7 and large del(7q), as we did not find them in MDS, JMML and AML cases. Other mutations or acquired abnormalities must be associated with those cases.
In sum, our study demonstrates for the first time detection of EZH2 mutations in patients with aggressive myeloid malignancies. EZH2 was frequently associated with UPD7q or 7q36.1 microdeletion, but not monosomy 7 and del(7q). Similar to previously identified mutations in UTX and ASXL1 in myeloid malignancies, EZH2 is a polycomb-associated gene. Our findings support an increasing possibility that mutations in these genes, together with TET2, represent a new class of molecular lesions conveying a clonal epigenetic instability phenotype. Consequently, mutations involved in epigenetic regulation can constitute leukemogenic events.
Recent years have seen the development of a number of new small molecule therapies for the treatment of myeloma and as a result of their introduction there have been significant improvements in patient survival. However, patients continue to relapse, and the current challenge is to develop therapies able to effectively treat these refractory cases. An emerging feature of the use of single, highly specific molecules is that they can be clinically ineffective because of the redundancy in the pathway targeted and compensatory changes induced by drug exposure. Consequently therapeutic efficacy is reliant on the development of effective combinations targeting synergistic pathways.
A simplified view of the function and biology of plasma cells is that they exist to produce immunoglobulin and this can provide a differential marker, which can be targeted. The requirement for immunoglobulin production means that the myeloma plasma cell is reliant upon the unfolded protein response (UPR) and molecular chaperones for survival. 1 Heat shock protein (Hsp) 90 is a molecular chaperone that has an important role in the pathophysiology of myeloma and represents a relevant therapeutic target. 2, 3 It fulfils two essential roles in plasma cells: firstly it is a major pro-survival chaperone, which associates with and stabilizes an extensive range of signal transducers important to plasma cell survival and proliferation (insulin-like growth factor-1, vascular endothelial growth factor, RAF and p42/44 mitogenactivated protein kinase), cell cycle regulation (AKT and nuclear factor-kB), migration (phosphoinositide 3-kinase) and antiapoptotic (nuclear factor-kB) pathways. Secondly, it has a central role in the UPR, which is responsible for ensuring the correct folding of nascent immunoglobulin, as well as providing survival signals for clonal expansion. Although targeting these pathways using inhibitors of Hsp90 has proved successful in myeloma preclinical models, preliminary results in patients suggest that combinations of agents will be required for clinical use.
To provide a rationale for the development of effective mechanism-based clinical combinations, we have tested the hypothesis that the induction of the Hsp70 family member, Hsp72, after treatment with an Hsp90 inhibitor, protects myeloma cells from apoptosis by enabling cells to increase their ability to fold damaged proteins. Hence inhibition of the function of Hsp72 may enhance the apoptosis induced by Hsp90 inhibition. We have therefore investigated the role of Hsp72 in myeloma using two chemical compounds, which have been shown to inhibit the protective effects of Hsp70, triptolide and KNK437. To confirm the impact of Hsp72 inhibition, we have verified these findings using small hairpin RNA (shRNA) specifically directed against Hsp72.
Our results show that after treatment with the Hsp90 inhibitor 17-AAG for 24 h, myeloma cells increase the protein level of Hsp72. Combination treatment with KNK437 or triptolide blocks this increase ( Figure 1a ) and results in a decrease in proliferation compared with treatment with 17-AAG alone. Using a series of 16 concentrations of these agents applied in combination for a period of 4 days, we demonstrate that the concomitant application of 17-AAG with either of these analysis of the dependence of drug-induced cell death on caspasedependent cell death pathways. Cells were pretreated with Z-VAD-FMK (Z) (50 mM) followed by the drugs alone or in combination 24 h. Samples were analyzed by annexin V/PI staining and the % of apoptotic cells displayed. Calculated P-values showed that there was a significant difference between T and T þ Z (P ¼ 0.019) and between 17 þ T and 17 þ T þ Z (P ¼ 0.034).
n indicates statistically significant P-values o0.05. (f) Upper panel: myeloma cells transfected with P, C1 or C4 shRNA were treated with 17-AAG and cell proliferation measured by WST-1 assay over a 4-day period. Lower panel: western blot analysis of Hsp72 expression after transduction with Hsp72 shRNAs: P ¼ control, scrambled shRNA plasmid transfected cells. C1 and C4 ¼ transfected cells expressing two different Hsp72 shRNAs. All experiments were performed in triplicate and, unless otherwise stated representative data using H929 cells is shown throughout.
